Loading...
Loading...
Deutsche Bank initiated coverage on Sarepta Therapeutics
SRPT with a Buy rating and a $45.00 price target.
Deutsche Bank analyst Robyn Karnauskas commented, "Sarepta is developing a RNA modulator, Eteplirsen, for the treatment of Duchenne Muscular Dystrophy (DMD). While our checks indicate Eteplirsen is unlikely to get accelerated approval, we see approval likely by mid-2015. We see Eteplirsen as having better safety profile versus its competitor Drisapersen that will allow it to take majority share. We see fair-value of Eteplirsen in the US only at $45/share & tremendous upside if the street assigns value to EU or other exon therapy opportunities."
Sarepta Therapeutics closed at $33.03 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in